Panoramica dell'azienda
Ginkgo Bioworks Holdings, Inc. operates as a specialized developer of cell engineering platforms within the United States, offering comprehensive research and development solutions alongside essential cell engineering tools. The company functions within the broader Healthcare sector, specifically categorized under the Biotechnology industry, an environment characterized by high capital requirements and significant regulatory scrutiny. As a mid-sized entity in this landscape, the company maintains a market capitalization of $398.17M, supported by an annual recurring revenue of $170.16M and a workforce comprising 485 employees. These financial dimensions indicate that the organization operates with a substantial asset base relative to its earnings, suggesting a business model that prioritizes long-term platform development over immediate profitability, a common trait in the biotechnology sector where market cap often reflects potential future cash flows rather than current operational gains.
Salute finanziaria
The company reported total revenue of $170.16M over the trailing twelve months, yet it posted a net income of -$312,763,008 and an EBITDA of -$267,822,000, revealing a cost structure where expenses significantly outpace gross receipts. This disparity between revenue and net income highlights an operating environment with high fixed costs and substantial research and development expenditures that absorb nearly double the revenue generated. Free cash flow stands at -$72,883,000, indicating that the company is burning cash to fund its operations and growth initiatives, which limits its immediate financial flexibility and reliance on external capital sources. The gross margin is reported at 72.4%, demonstrating strong pricing power or low cost of goods sold, whereas the operating margin of -209.7% and profit margin of -183.8% underscore the intense overhead burdens typical of early-stage biotechnology firms. Liquidity analysis shows a cash balance of $422.62M against total debt of $439.88M, resulting in a debt-to-equity ratio of 86.49, which characterizes a highly leveraged balance sheet where liabilities slightly exceed available liquid assets. Despite this leverage, the current ratio of 4.92 suggests robust short-term liquidity, implying the company possesses ample current assets to cover its short-term obligations. Furthermore, the return on equity is -51.1% and the return on assets is -15.4%, metrics that collectively reveal that management is currently deploying shareholder capital and assets in a manner that generates negative returns, a situation often observed in growth-stage companies seeking to establish market presence before achieving commercial scale.
Valutazione del valore
Valuation multiples for the company present a complex picture, with a trailing P/E ratio marked as N/A due to lack of profitability and a forward P/E of -1.77, which implies that the market is not valuing the company based on current or near-term earnings power. The price-to-book ratio stands at 0.74, indicating that the market values the company at a discount to its book value, a scenario frequently seen in distressed or turnaround situations rather than premium growth stocks. Alternative valuation metrics such as the price-to-sales ratio of 2.34 and an EV/EBITDA of -1.46 suggest that investors are pricing the stock based on revenue generation and enterprise value multiples rather than earnings, reflecting a bet on future revenue expansion rather than current profitability. The stock has traded within a range defined by a 52-week high of $17.58 and a 52-week low of $5.37, and while the exact current trading price is not explicitly stated in the provided data, the valuation metrics suggest the market is currently pricing the asset significantly below its recent peak performance levels. The beta of 1.57 indicates that the stock exhibits high volatility, moving 57% more than the broader market, which underscores the speculative nature of the investment and the sensitivity of the price to market sentiment shifts in the biotechnology sector.
Growth & Income
Revenue growth year-over-year has contracted by -23.8%, while earnings growth is listed as N/A, indicating that the company is currently experiencing a decline in top-line sales rather than a period of expansion. The absence of positive earnings growth relative to revenue further highlights the structural challenges the firm faces, as negative earnings persist despite revenue fluctuations. Ginkgo Bioworks does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the company retains all earnings to fund operations and research rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology firms that prioritize capital allocation toward platform development over income distribution, effectively treating the company as a non-income-generating vehicle for current holders. The overall growth and income profile is defined by significant revenue contraction, negative earnings, and a complete lack of dividend distribution, painting a picture of a firm in a defensive or restructuring phase rather than a high-growth expansion phase.